Royce & Associates LP Sells 38,447 Shares of Transcat, Inc. (NASDAQ:TRNS)

Royce & Associates LP reduced its stake in shares of Transcat, Inc. (NASDAQ:TRNS) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 473,254 shares of the scientific and technical instruments company’s stock after selling 38,447 shares during the quarter. Royce & Associates LP owned 5.08% of Transcat worth $50,042,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of TRNS. Jones Financial Companies Lllp grew its stake in shares of Transcat by 686.7% during the fourth quarter. Jones Financial Companies Lllp now owns 354 shares of the scientific and technical instruments company’s stock valued at $37,000 after buying an additional 309 shares during the last quarter. Morgan Dempsey Capital Management LLC bought a new stake in shares of Transcat in the fourth quarter worth about $143,000. SG Americas Securities LLC bought a new stake in shares of Transcat in the fourth quarter worth about $182,000. Captrust Financial Advisors bought a new stake in shares of Transcat in the third quarter worth about $201,000. Finally, Walleye Capital LLC bought a new stake in shares of Transcat in the third quarter worth about $216,000. 98.34% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Craig D. Cairns acquired 1,200 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $77.02 per share, for a total transaction of $92,424.00. Following the acquisition, the director now directly owns 1,910 shares in the company, valued at approximately $147,108.20. The trade was a 169.01 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.30% of the company’s stock.

Wall Street Analyst Weigh In

TRNS has been the topic of several recent analyst reports. HC Wainwright cut their target price on Transcat from $126.00 to $106.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Oppenheimer cut Transcat from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 29th. Craig Hallum raised their target price on Transcat from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. StockNews.com cut Transcat from a “hold” rating to a “sell” rating in a research note on Wednesday, February 5th. Finally, Northland Securities restated a “market perform” rating and issued a $85.00 price objective (down from $110.00) on shares of Transcat in a report on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Transcat has a consensus rating of “Hold” and a consensus price target of $111.50.

Transcat Stock Performance

Shares of TRNS opened at $72.57 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.42 and a quick ratio of 1.98. Transcat, Inc. has a one year low of $70.47 and a one year high of $147.12. The company has a 50-day simple moving average of $86.32 and a two-hundred day simple moving average of $104.38. The firm has a market capitalization of $675.55 million, a PE ratio of 39.23 and a beta of 0.66.

Transcat (NASDAQ:TRNS) last released its earnings results on Monday, January 27th. The scientific and technical instruments company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.07. Transcat had a net margin of 6.22% and a return on equity of 7.23%. During the same quarter last year, the business earned $0.56 earnings per share. On average, analysts anticipate that Transcat, Inc. will post 2.3 EPS for the current fiscal year.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.